Gynecologic Oncology Reports最新文献

{"title":"Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome","authors":"Shilpa Mokshagundam ,&nbsp;Mrinal M. Patnaik ,&nbsp;Luigi A. DeVitis ,&nbsp;Simrit K. Warring ,&nbsp;Megan E. Grudem ,&nbsp;Matthew S. Block","doi":"10.1016/j.gore.2025.101806","DOIUrl":"10.1016/j.gore.2025.101806","url":null,"abstract":"<div><h3>Objective</h3><div>As the use of poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) increases in the management of advanced ovarian cancer, therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) may be observed more frequently. Strategies for management of this unique condition are needed.</div></div><div><h3>Methods</h3><div>In this case report, we demonstrate the case of a patient with advanced ovarian cancer and a pathogenic BRCA1 mutation who developed MDS following 4 years of maintenance PARPi.</div></div><div><h3>Results</h3><div>Management of therapy-related MDS/AML is variable. In addition, subsequent oncologic treatments may be limited due to risk of MDS/AML recurrence with exposure to cytotoxic therapies and/or PARPi. Risk for MDS/AML recurrence can be monitored and predicted by evaluation for clonal hematopoiesis. This patient underwent autologous stem cell transplant. After subsequent disease recurrence, she underwent repeat germline testing which showed BRCA1 wildtype. In addition, no clonal hematopoietic clones were identified using a specialized institutional assay. For this reason and given previous durable response to PARPi, the patient was re-treated with a PARPi.</div></div><div><h3>Conclusions</h3><div>This case highlights the unique management of therapy-related MDS/AML and underscores the importance of multidisciplinary care in determining safety of subsequent cancer-directed therapies in this patient population.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101806"},"PeriodicalIF":1.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between abnormal p53 expression and high-risk histology in endometrial cancers and living in proximity to hog concentrated animal feeding operations in North Carolina","authors":"Jaye Boissiere ,&nbsp;Samantha M. Thomas ,&nbsp;Yueqi Gu ,&nbsp;Sarah Linhart ,&nbsp;Lauren March ,&nbsp;Andrew Berchuck ,&nbsp;Brittany Davidson ,&nbsp;Emma Rossi ,&nbsp;Laura Havrilesky ,&nbsp;Angeles Alvarez Secord","doi":"10.1016/j.gore.2025.101801","DOIUrl":"10.1016/j.gore.2025.101801","url":null,"abstract":"<div><h3>Objective</h3><div>Prior research demonstrated a 2.27-fold increase in uterine cancer mortality among North Carolinians living near hog concentrated animal feeding operations (CAFOs). Endometrial cancer (EC) accounts for 90% of uterine cancer cases. Mutation and abnormal expression of the <em>TP53</em> gene is a frequent causative alteration in aggressive forms ECs. We investigated whether increased proximity to hog CAFOs was associated with abnormal p53 expression, aggressive histologic subtypes, and increased mortality.</div></div><div><h3>Methods</h3><div>Patients with a pathologic diagnosis of EC were enrolled into the study between 2019 and 2024. Demographic and clinicopathologic data were abstracted from the electronic health record. Unadjusted survival was estimated with the Kaplan-Meier method with log-rank tests. Cox proportional hazards models were used to estimate associations between residing in a county classified as having CAFOs or no CAFOs, serous and carcinosarcoma EC subtypes, abnormal p53 expression, and survival.</div></div><div><h3>Results</h3><div>Of the 278 enrolled participants, the median age was 70.5 years, and 40.6 % resided in a CAFO county at the time of EC diagnosis. There was no association between abnormal p53 expression (46.9 % vs 51.5 %, p = 0.45), serous histology (27.4 % vs 35.2 %, p = 0.39), or carcinosarcoma subtype (12.4 % vs 10.3 %, p = 0.39) and residence in a CAFO vs non-CAFO county. Unadjusted overall survival rates were similar between those in counties with and without CAFOs (log-rank p = 0.62).</div></div><div><h3>Conclusions</h3><div>This study did not demonstrate an association between CAFO county status and abnormal p53 expression or aggressive histologic subtypes. Further studies are warranted to investigate the causes of previously established mortality differences in uterine cancer patients by CAFO proximity.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101801"},"PeriodicalIF":1.2,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ivermectin and gynecologic cancer: What’s the data?","authors":"Vaidehi Mujumdar ,&nbsp;Marilyn Huang ,&nbsp;Lindsey Chippendale Smith ,&nbsp;Fernanda Musa","doi":"10.1016/j.gore.2025.101803","DOIUrl":"10.1016/j.gore.2025.101803","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101803"},"PeriodicalIF":1.2,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing decision-making on opportunistic salpingo-oophorectomy for ovarian cancer prevention in women with gastrointestinal cancers undergoing intra-abdominal surgery","authors":"Jaekyung Bae ,&nbsp;Uisuk Kim ,&nbsp;Sokbom Kang","doi":"10.1016/j.gore.2025.101800","DOIUrl":"10.1016/j.gore.2025.101800","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the attitudes of women with non-gynecologic cancers undergoing intra-abdominal surgery toward opportunistic salpingo-oophorectomy (OSO) for ovarian cancer prevention, and to identify factors influencing their decision-making regarding prophylactic surgery.</div></div><div><h3>Methods</h3><div>From July 2022 to August 2023, a questionnaire-based survey was conducted among women aged 40 years or older scheduled for intra-abdominal surgery for gastric or colorectal cancer at the National Cancer Center Korea. After providing information on ovarian cancer risk and laparoscopic salpingo-oophorectomy, including its benefits and potential risks, data were collected on participants’ cancer history, menopausal status, education level, income, family history of cancer, concerns about ovarian cancer, and perceptions of cancer treatment. Quality of life and menopausal symptoms were assessed using the EuroQol 5 Dimensions 3 Levels questionnaire (EQ-5D-3L) and the Menopause Rating Scale.</div></div><div><h3>Results</h3><div>Overall, 60.2 % of the respondents (59 out of 98) were willing to undergo OSO at the time of their surgery. The most common reason for declining OSO was a lack of concern about ovarian cancer (21/39, 53.8 %), followed by concerns about potential declines in quality of life (13/39, 33.3 %). Personal or familial cancer history, concerns about cancer treatment, perceived risk of ovarian cancer, menopausal symptoms, and overall quality of life did not significantly influence the decision to accept or refuse OSO.</div></div><div><h3>Conclusions</h3><div>The choice to undergo OSO appears to be driven more by personal perception of ovarian cancer risk and worries about postoperative quality of life than by measurable menopausal symptoms, current health-related quality of life, or previous cancer-related experiences. These findings offer important guidance for the development of OSO-centered ovarian cancer prevention strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101800"},"PeriodicalIF":1.2,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of Anti-Hu and Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with stage IV adenocarcinoma of Müllerian origin","authors":"Saad Rashid ,&nbsp;Suneha Pocha ,&nbsp;Nada Saleh ,&nbsp;Erin Ozminkowski ,&nbsp;Vijayta Geeta Bansal ,&nbsp;Vibhav Bansal","doi":"10.1016/j.gore.2025.101804","DOIUrl":"10.1016/j.gore.2025.101804","url":null,"abstract":"<div><h3>Introduction</h3><div>Paraneoplastic cerebellar degeneration (PCD) is a rare neurological complication of malignancies, resulting from autoimmune responses targeting antigens shared by neurons and tumors. It is characterized by progressive cerebellar dysfunction, including ataxia and dysarthria, and is associated with anti-onconeuronal antibodies such as Anti-Yo and Anti-Hu. While most cases of Anti-Hu-associated PCD occur in patients with small cell lung cancer, their association with gynecologic malignancies is exceedingly rare. This is the first reported case in the literature of a patient with adenocarcinoma of Müllerian origin complicated by Anti-Hu PCD.</div></div><div><h3>Case</h3><div>We present the case of a 73-year-old female with stage IV adenocarcinoma of Müllerian origin who presented with worsening ataxia and dysarthria after undergoing outpatient chemoimmunotherapy to treat her gynecologic malignancy. CT and MRI Brain imaging revealed nonspecific findings, but cerebrospinal fluid (CSF) analysis revealed the presence of positive anti-Hu and anti-Zic4 antibodies, consistent with a diagnosis of PCD. Despite treatment with high-dose intravenous corticosteroids and plasmapheresis in the acute setting, the patient displayed minimal improvement and continued to experience persistent neurological impairment.</div></div><div><h3>Conclusion</h3><div>Despite advancements in diagnostic criteria and the availability of multiple types of therapies, outcomes for PCD remain poor. This is especially notable for cases associated with Anti-Hu antibodies. This case highlights the importance of considering PCD in the differential diagnosis of patients with malignancies and unexplained neurological symptoms. Furthermore, it highlights the critical need for continued research to refine diagnostic methods and develop more effective, evidence-based treatment strategies to improve outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101804"},"PeriodicalIF":1.2,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144595867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-grade endometrial cancer presents with malignancy-associated disseminated intravascular coagulation: A case report","authors":"Jennifer Hansen,&nbsp;Andreea Dinicu,&nbsp;Johanna Kelley,&nbsp;Lindsey Beffa","doi":"10.1016/j.gore.2025.101802","DOIUrl":"10.1016/j.gore.2025.101802","url":null,"abstract":"<div><div>Malignancy-associated DIC is uncommon and when it does occur, is often associated with hematologic malignancies rather than solid tumors. In this case, we describe an unusual case when a patient with advanced stage high-grade endometrial adenocarcinoma presented to care with vision loss and deep vein thrombosis, found to be in disseminated intravascular coagulation (DIC). The patient suffered many complications from her DIC, which was briefly managed with systemic therapy for her underlying malignancy but ultimately led to her death. DIC has been reported in the literature rarely for gynecologic malignancies, and never as presenting symptom for high-grade endometrial adenocarcinoma.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101802"},"PeriodicalIF":1.2,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study","authors":"Alexandra R. Steck ,&nbsp;Barbara Mahar ,&nbsp;Jovana Y. Martin ,&nbsp;Timothy J. McElrath ,&nbsp;Patrick F. Timmins III ,&nbsp;Joyce N. Barlin","doi":"10.1016/j.gore.2025.101793","DOIUrl":"10.1016/j.gore.2025.101793","url":null,"abstract":"<div><h3>Objective</h3><div>To report on the efficacy of pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide used in combination for patients with platinum resistant recurrent ovarian cancer in community practice.</div></div><div><h3>Methods</h3><div>This retrospective observational study was conducted at a single gynecologic oncology practice in Albany, NY. Patients that had a diagnosis of platinum-resistant ovarian cancer (PROC) received intravenous pembrolizumab (200 mg) and bevacizumab (15 mg/kg) every 3 weeks, with oral cyclophosphamide (50 mg) once daily during the treatment cycle until disease progression, toxicity, or withdrawal of consent. Treatment response was determined using imaging and CA-125 levels.</div></div><div><h3>Results</h3><div>Nineteen patients with PROC were included. There were 17 high grade serous and 2 clear cell cancers. Of the 19 patients studied, 10 had Stage IIIC disease at diagnosis. The mean (SD) number of prior lines of treatment was 4.6 (2.0) with 94.7 % of patients having prior exposure to bevacizumab. Four patients had partial responses, 4 had stable disease, and 11 had progressive disease. The objective response rate was 21.1 percent, and the total clinical benefit rate was 42.1 percent. The median progression free survival (PFS) was 4.0 months, and the overall survival (OS) was 17.0 months. The most common adverse events were fatigue (47.4 %), nausea (31.6 %), and abdominal pain (26.3 %).</div></div><div><h3>Conclusion</h3><div>The combination of pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide was well tolerated and demonstrated a 21.1 percent response rate in a heavily pre-treated platinum resistant ovarian cancer population, warranting future investigation of subgroups who may derive benefit from this regimen under such conditions.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101793"},"PeriodicalIF":1.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144536019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers","authors":"Bhavana Pothuri ,&nbsp;Michele Muir ,&nbsp;Jean Hurteau ,&nbsp;John Farley ,&nbsp;Michelle D.S. Lightfoot ,&nbsp;Summer Dewdney ,&nbsp;Tara Castellano ,&nbsp;John K. Chan ,&nbsp;Sharad Ghamande ,&nbsp;Al Asante-Facey ,&nbsp;Marina Stasenko ,&nbsp;B.J. Rimel ,&nbsp;Electra D. Paskett","doi":"10.1016/j.gore.2025.101799","DOIUrl":"10.1016/j.gore.2025.101799","url":null,"abstract":"<div><h3>Background</h3><div>Significant disparities exist in the care of patients with gynecologic malignancies. Higher incidences of gynecologic malignancies among underrepresented subpopulations (eg, racial, ethnic, and/or LGBTQAI+) and lack of representative enrollment within clinical trials have highlighted the need to improve healthcare equity. We aimed to identify barriers to equitable health care and clinical trial participation for specific diverse populations of patients with gynecologic malignancies and to identify potential solutions for overcoming these barriers.</div></div><div><h3>Methods</h3><div>A series of 4 live and 3 asynchronous advisory boards facilitated by GSK was conducted between January 2023 and July 2024; live advisory boards were population specific. Gynecologic oncologists, health researchers, advanced practice providers, patients, and patient advocacy group representatives who worked with and/or were themselves members of the focus population participated. Insights were compiled and analyzed to identify barriers and potential solutions across and within populations.</div></div><div><h3>Results</h3><div>Common barriers to equitable health care across all populations included cost, transportation, level of health literacy, and provider biases; 11 population-specific barriers were noted, with LGBTQAI+ patients described as facing the most barriers. Patient navigator involvement was identified as a feasible and highly impactful solution for breaking multiple barriers across various diverse populations.</div></div><div><h3>Conclusions</h3><div>Most barriers to equitable health care were population specific, affirming the need for continued consultation and discussions with members of communities and with individuals to address specific barriers and enact effective solutions. Engagement of patient navigators was identified as an important way to improve disparities within the care of gynecologic malignancies across all underrepresented patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101799"},"PeriodicalIF":1.2,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PAX1/SOX1 gene methylation as a detection and triage method for triage of high risk HPV-Positive women in cervical cancer screening","authors":"Ruyi Zhang ,&nbsp;Ye Li ,&nbsp;Yu Han ,&nbsp;Chang Guo ,&nbsp;Jie Guo ,&nbsp;Jie Sun ,&nbsp;Dengfeng Wang ,&nbsp;Xiatao Hu ,&nbsp;Jiao Li ,&nbsp;Xuanying Zhao ,&nbsp;Yiyuan Zhou ,&nbsp;Tingting Zhai ,&nbsp;Yuqiong Meng ,&nbsp;Jing Wang ,&nbsp;Wengao Chen","doi":"10.1016/j.gore.2025.101794","DOIUrl":"10.1016/j.gore.2025.101794","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the role of PAX1/SOX1 methylation testing in the triage of HPV-positive patients and compare its performance with traditional screening methods, including HPV genotyping and cytology.</div></div><div><h3>Methods</h3><div>A study was conducted from February 2024 to October 2024, involving women referred for colposcopy during the “two-cancer screening” in a specific region. Patients were grouped based on histopathological results [normal/cervicitis, cervical intraepithelial neoplasia 1 (CIN1), high-grade squamous intraepithelial lesion (HSIL), cervical cancer] and high-risk human papillomavirus (hrHPV) typing (HPV16/18 positive, other 12 hrHPV positive). Cervical exfoliated cell specimens were collected for PAX1/SOX1 methylation and liquid-based cytology testing. Methylation status was detected using a specific PCR-fluorescence probe kit, and cytology results were interpreted according to the 2022 Bethesda System (TBS) system.</div></div><div><h3>Results</h3><div>The study included 640 participants. The mean Ct values of PAX1 and SOX1 decreased with the progression of cervical lesions. In the detection of high grad CIN+ (HG-CIN + ) in HPV-positive women, PAX1/SOX1 methylation testing showed higher AUCs (PAX1: 0.84; SOX1: 0.83) compared to HPV genotyping and cytology. For non-16/18 hrHPV positive cases, methylation testing had a better balance of sensitivity and specificity in detecting ≥ CIN2 and ≥ CIN3 lesions. Methylation testing also had the potential to reduce unnecessary colposcopy referrals in HPV-positive patients with cytology.</div></div><div><h3>Conclusions</h3><div>PAX1/SOX1 methylation testing shows potential as an effective adjunct to traditional cervical cancer screening methods. It can better identify high-grade lesions in HPV-positive patients and may reduce unnecessary referrals. However, larger-scale studies and long-term follow-up are needed to confirm its efficacy and optimize its integration into routine screening protocols.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101794"},"PeriodicalIF":1.2,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional response to trastuzumab deruxtecan in recurrent neuroendocrine cervical cancer: A case report","authors":"Lauren Tostrud ,&nbsp;Brooke E. Howitt ,&nbsp;Margaret Mills ,&nbsp;Amer Karam ,&nbsp;Kristin L. Bixel","doi":"10.1016/j.gore.2025.101798","DOIUrl":"10.1016/j.gore.2025.101798","url":null,"abstract":"<div><h3>Objective</h3><div>Neuroendocrine cervical carcinomas (NECC) are a rare and aggressive cervical cancer subtype that account for 1–1.5 % of all cervical cancers. Treatment options for recurrent NECC are limited and anticipated response rates are low. Trastuzumab deruxtecan (T-DXd), an antibody drug conjugate with a topoisomerase I inhibitor payload, recently received FDA approval for previously treated patients with HER2+ (IHC3 + ) metastatic solid tumors. Data regarding use of T-DXd in NECC is very limited and it is unclear whether this histology was represented in the trial leading to approval. We sought to describe this unique case of a patient with recurrent NECC who experienced a complete and durable response to T-DXd.</div></div><div><h3>Methods</h3><div>This is a case report and review of the literature. Written informed consent was obtained by the patient prior to submission.</div></div><div><h3>Results</h3><div>We describe a 44-year-old patient with recurrent, metastatic NECC who progressed following two prior lines of therapy, the most recent of which included a multi-drug regimen with topotecan (a topoisomerase I inhibitor). IHC of her tumor tissue demonstrated 3 + HER 2 expression leading to the decision to proceed with treatment with T-DXd. She experienced a partial response (64 % decrease by RECIST) at C6 and subsequent complete response which has now been maintained for &gt; 1 year. She has tolerated therapy well with manageable toxicities and has not required treatment interruption to date.</div></div><div><h3>Conclusions</h3><div>This report demonstrates the role of biomarker driven therapy for rare and aggressive cancer subtypes such as NECC and demonstrates efficacy of T-DXd after previous exposure to topoisomerase I inhibitors.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101798"},"PeriodicalIF":1.2,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144489986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}